Program overview
Context
Indication: Recurrent Non-small Cell Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: National Cancer Institute (NCI)
cediranib maleate is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Recurrent Non-small Cell Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: National Cancer Institute (NCI)
Registry: 0/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 1/5
https://clinicaltrials.gov/study/NCT00245063
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT00245063 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | strict_eligibility_signal |